ATS Bioprosthesis Implanted in Switzerland
January 26, 2010 - Medical Device Daily
ATS Medical (Minneapolis) reported the first commercial implants of the ATS 3f Enable Aortic Bioprosthesis were recently performed at the University of Berne Hospital (Berne, Switzerland) by Lars Englberger, MD, Mario Stalder, MD, and Professor Thierry Carrel. The procedures were completed using a sutureless technique and the patients are recovering with no complications.
The ATS 3f Enable valve is the first surgical aortic valve replacement approved for commercial use that is implanted using a sutureless technique. The Enable valve combines the ATS 3f Aortic Bioprosthesis with more than eight years of proven clinical performance and a self-expanding Nitinol frame to hold the valve in its optimal position eliminating the need for conventional sutures. This design allows the Enable valve to be folded into a small diameter and placed through a minimally invasive incision. The Enable valve preserves native stress distribution and provides a large orifice area with laminar flow for excellent hemodynamics.
Carrel, chief of Cardiac Surgery at the University of Berne said, "The implants went smoothly. There were no paravalvular leaks and the valves provide excellent hemodynamic performance with low single digit gradients. The Enable valve will help us expand our number of minimally invasive procedures."
